A Modified Targetoid Feature Emphasizing Thin-Rim APHE to Improve the Diagnostic Performance of LI-RADS for Malignant Hepatic Tumors

References

• American College of Radiology. Liver Imaging reporting and data system version 2018. Available from: http://www.acr.org/QualitySafety/Resources/LIRADS. Accessed April 04, 2024.
   Google Scholar
• Huang Z, Zhou PP, Li SS, Li K. CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors. Cancer Imaging. 2023;23(1):24. doi:10.1186/s40644-023-00541-2
   PubMed Web of Science ®Google Scholar
• Chernyak V, Fowler KJ, Kamaya A, et al. Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology. 2018;289(3):816–830. doi:10.1148/radiol.2018181494
   PubMed Web of Science ®Google Scholar
• Park JG, Jung GS, Yun JH, et al. Percutaneous transluminal forceps biopsy in patients suspected of having malignant biliary obstruction: factors influencing the outcomes of 271 patients. Eur Radiol. 2017;27(10):4291–4297. doi:10.1007/s00330-017-4796-x
   PubMed Web of Science ®Google Scholar
• An C, Park S, Chung YE, et al. Curative resection of single primary hepatic malignancy: liver imaging reporting and data system category LR-M portends a worse prognosis. AJR Am J Roentgenol. 2017;209(3):576–583. doi:10.2214/ajr.16.17478
   PubMed Web of Science ®Google Scholar
• Jang JK, Choi SH, Byun JH, et al. New strategy for liver imaging reporting and data system category M to improve diagnostic performance of MRI for hepatocellular carcinoma ≤ 3.0 cm. Abdom Radiol. 2022;47(7):2289–2298. doi:10.1007/s00261-022-03538-w
   PubMed Web of Science ®Google Scholar
• Li Y, Ni X, Liu X, et al. Prognosis of primary liver cancer based on LI-RADS classification with extracellular agent-enhanced MRI. J Hepatocell Carcinoma. 2023;10:399–411. doi:10.2147/jhc.S394840
   PubMed Web of Science ®Google Scholar
• Kim DH, Choi SH, Park SH, et al. Liver imaging reporting and data system category M: a systematic review and meta-analysis. Liver Int. 2020;40(6):1477–1487. doi:10.1111/liv.14420
   PubMed Web of Science ®Google Scholar
• Kim YY, Kim MJ, Kim EH, Roh YH, An C. Hepatocellular carcinoma versus other hepatic malignancy in cirrhosis: performance of LI-RADS version 2018. Radiology. 2019;291(1):72–80. doi:10.1148/radiol.2019181995
   PubMed Web of Science ®Google Scholar
• Kierans AS, Makkar J, Guniganti P, et al. Validation of liver imaging reporting and data system 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma. J Magn Reson Imaging. 2019;49(7):e205–e215. doi:10.1002/jmri.26329
   PubMed Web of Science ®Google Scholar
• Lee SM, Lee JM, Ahn SJ, Kang HJ, Yang HK, Yoon JH. LI-RADS version 2017 versus version 2018: diagnosis of hepatocellular carcinoma on gadoxetate disodium-enhanced MRI. Radiology. 2019;292(3):655–663. doi:10.1148/radiol.2019182867
   PubMed Web of Science ®Google Scholar
• Tang A, Bashir MR, Corwin MT, et al. Evidence Supporting LI-RADS Major Features for CT- and MR imaging–based diagnosis of hepatocellular carcinoma: a systematic review. Radiology. 2018;286(1):29–48. doi:10.1148/radiol.2017170554
   PubMed Web of Science ®Google Scholar
• Park HJ, Kim YK, Cha DI, et al. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category. Clin Radiol. 2020;75(6):478.e13–478.e23. doi:10.1016/j.crad.2020.01.002
   PubMed Web of Science ®Google Scholar
• van der Pol CB, Lim CS, Sirlin CB, et al. Accuracy of the liver imaging reporting and data system in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review. Gastroenterology. 2019;156(4):976–986. doi:10.1053/j.gastro.2018.11.020
   PubMed Web of Science ®Google Scholar
• Min JH, Lee MW, Park HS, et al. LI-RADS version 2018 targetoid appearances on gadoxetic acid-enhanced MRI: interobserver agreement and diagnostic performance for the differentiation of HCC and Non-HCC malignancy. AJR Am J Roentgenol. 2022;219(3):421–432. doi:10.2214/ajr.22.27380
   PubMed Web of Science ®Google Scholar
• Kim JH, Joo I, Lee JM. Atypical appearance of hepatocellular carcinoma and its mimickers: how to solve challenging cases using gadoxetic acid-enhanced liver magnetic resonance imaging. Korean J Radiol. 2019;20(7):1019–1041. doi:10.3348/kjr.2018.0636
   PubMed Web of Science ®Google Scholar
• Min JH, Kim JM, Kim YK, et al. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions. Eur Radiol. 2022;32(2):912–922. doi:10.1007/s00330-021-08124-0
   PubMed Web of Science ®Google Scholar
• Zheng W, Huang H, She D, et al. Added-value of ancillary imaging features for differentiating hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma on Gd-BOPTA-enhanced MRI in LI-RADS M. Abdom Radiol. 2022;47(3):957–968. doi:10.1007/s00261-021-03380-6
   PubMed Web of Science ®Google Scholar
• Santillan C, Fowler K, Kono Y, Chernyak V. LI-RADS major features: CT, MRI with extracellular agents, and MRI with hepatobiliary agents. Abdom Radiol. 2018;43(1):75–81. doi:10.1007/s00261-017-1291-4
   PubMed Web of Science ®Google Scholar
• Choi SY, Kim YK, Min JH, et al. Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging. Eur Radiol. 2018;28(6):2549–2560. doi:10.1007/s00330-017-5196-y
   PubMed Web of Science ®Google Scholar
• Cha DI, Choi GS, Kim YK, et al. Extracellular contrast-enhanced MRI with diffusion-weighted imaging for HCC diagnosis: prospective comparison with gadoxetic acid using LI-RADS. Eur Radiol. 2020;30(7):3723–3734. doi:10.1007/s00330-020-06753-5
   PubMed Web of Science ®Google Scholar
• Li F, Li Q, Liu Y, et al. Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017. Eur Radiol. 2020;30(1):461–470. doi:10.1007/s00330-019-06317-2
   PubMed Web of Science ®Google Scholar
• Kang Y, Lee JM, Kim SH, Han JK, Choi BI. Intrahepatic mass-forming cholangiocarcinoma: enhancement patterns on gadoxetic acid-enhanced MR images. Radiology. 2012;264(3):751–760. doi:10.1148/radiol.12112308
   PubMed Web of Science ®Google Scholar
• Murakami T, Nakamura H, Tsuda K, et al. Contrast-enhanced MR imaging of intrahepatic cholangiocarcinoma: pathologic correlation study. J Magn Reson Imaging. 1995;5(2):165–170. doi:10.1002/jmri.1880050210
   PubMed Web of Science ®Google Scholar